Will knowledge of human genome variation result in changing cancer paradigms?

BioEssays

Volumn 29, Issue 7, 2007, Pages 678-685

  Gottlieb, Bruce ^a,b,c   Beitel, Lenore K ^a,b   Trifiro, Mark ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c JOHN ABBOTT COLLEGE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

TELOMERASE;

CANCER; CARCINOGENESIS; CELL DIFFERENTIATION; CELL PROLIFERATION; GENE IDENTIFICATION; GENE MUTATION; GENE NUMBER; GENETIC VARIABILITY; HUMAN; REVIEW; TELOMERE;

GENE EXPRESSION REGULATION, NEOPLASTIC; GENOME, HUMAN; HUMANS; MODELS, BIOLOGICAL; NEOPLASMS; VARIATION (GENETICS);

EID: 34447328752     PISSN: 02659247     EISSN: None     Source Type: Journal    
DOI: 10.1002/bies.20595     Document Type: Review

References (59)

1. Centers for Disease Control. 2002. Recent trends in mortality rates for four major cancers, by sex and race/ethnicity - United States, 1990-1998. Morbidity and Mortality Weekly Report 51:49-53.
2. Weinberg RA. 1998. One renegade cell: How cancer begins. New York: Basic Books.
3. Alberts B, Johnson A, Lewis J, Raff M, Roberts K, et al. 2001. Molecular Biology of the Cell. New York, NY: Garland Publishing Inc. p 1313-1362.
4. Wang TL, Rago C, Silliman N, Ptak J, Markowitz S, et al. 2002. Prevalence of somatic alterations in the colorectal cancer cell genome. Proc Natl Acad Sci USA 99:3076-3080.
5. Frank SA, Nowak MA. 2004. Problems of somatic mutation and cancer. BioEssays 26:291-299.
6. Soto AM, Sonnenschein C. 2004. The somatic mutation theory of cancer: Growing problems with paradigm? BioEssays 26:1097-1106.
7. Harris H. A long view of fashions in cancer research. 2005. BioEssays 27:833-838.
8. Hastie ND, Dempster M, Dunlop MG, Thompson AM, Green DA, et al. 1990. Telomere reduction in human colorectal carcinoma and with ageing. Nature 346:866-868.
9. Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, et al. 1994. Specific association of human telomerase activity with immortal cells and cancer. Science 266:2011-2015.
10. Blackburn EH, Greider CW, Szostak JW. 2006. Telomeres and telomerase: the path from maize, Tetrahymena and yeast to human cancer and aging. Nat Med 12:1133-1138.
11. Reya T, Morrison SJ, Clarke MF, Weissman IL. 2001. Stem cells, cancer, and cancer stem cells. Nature 414:105-111.
12. Feinberg AP. 2005. A genetic approach to cancer epigenetics. Cold Spring Harb Symp Quant Biol 70:335-341.
13. Klein G. 2005. Epigenetics: Surveillance team against cancer. Nature 434:150.
14. Albertson DG. 2006. Gene amplification in cancer. Trends in Genetics 22:447-455.
15. Alvarez JV, Perez D, Chodosh LA. 2006. mILC-ing the mouse mammary gland: A model for invasive lobular carcinoma. Cancer Cell 10:347-349.
16. Garber K. 2006. Realistic rodents? Debate grows over new mouse models of cancer. J Natl Cancer Inst 98:1176-1178.
17. Walsh T, King M-C. 2007. Ten genes for inherited breast cancer. Cancer Cell 11:103-105.
18. Sampieri K, Hadjistilianou T, Mari F, Speciale C, Mencarelli MA, et al. 2006. Mutational screening of the RB1 gene in Italian patients with retinoblastoma reveals 11 novel mutations. J Hum Genet 51:209-216.
19. Conrad DF, Jakobsson M, Coop G, Wen X, Wall JD, et al. 2006. A worldwide survey of haplotype variation and linkage disequilibrium in the human genome. Nat Genet 38:1251-1260.
20. Sjoblom T, Jones S, Wood LD, Parsons DW, Lin J, et al. 2006. The consensus coding sequences of human breast and colorectal cancers. Science 314:268-274.
21. Baker SG, Kaprio J. 2006. Common susceptibility genes for cancer: Search for the end of the rainbow. BMJ 332:1150-1152.
22. Ching WJ. 2007. Limits to the human cancer genome project. Science 315:762.
23. Loeb LA, Bielas JH. 2007. Limits to the human cancer genome project. Science 315:762.
24. Strauss BS. 2007. Limits to the human cancer genome project. Science 315:762-763.
25. Gerard RW. 1957. Units and concepts of biology. Science 125:429-433.
26. Rubin H. 2006. What keeps cells in tissues behaving normally in the face of myriad mutations? BioEssays 28:515-524.
27. Heppner GH. 1984. Tumor heterogeneity. Cancer Res 44:2259-2265.
28. Mora J, Cheung NK, Gerald WL. 2001. Genetic heterogeneity and clonal evolution in neuroblastoma. Br J Cancer 85:182-189.
29. Van der Poel HG, Oosterhof GO, Schaafsma HE, Debruyne FM, Schalken JA. 1997 Intratumoral nuclear morphologic heterogeneity in prostate cancer. Urology 49:652-657.
30. Owonikoko T, Rees M, Gabbert HE, Sarbia M. 2002. Intratumoral genetic heterogeneity in Barrett adenocarcinoma. Am J Clin Pathol 117:558-566.
31. Aubele M, Mattis A, Zitzelsberger H, Walch A, Kremer M, et al. 1999. Intratumoral heterogeneity in breast carcinoma revealed by laser-microdissection and comparative genomic hybridization. Cancer Genet Cytogenet 110:94-102.
32. Losi L, Baisse B, Bouzourene H, Benhattar J. 2005. Evolution of intratumoral genetic heterogeneity during colorectal cancer progression. Carcinogenesis 26:916-922.
33. Takata M, Morita R, Takehara K. 2000. Clonal heterogeneity in sporadic melanomas as revealed by loss-of-heterozygosity analysis. Int J Cancer 85:492-497.
34. Ruiz-Cerda JL, Hernandez M, Sempere A, O'Connor JE, Kimler BF, et al. 1999. Intratumoral heterogeneity of DNA content in renal cell carcinoma and its prognostic significance. Cancer 86:664-671.
35. Struikmans H, Rutgers DH, Hordijk GJ, van der Tweel I, Battermann JJ. 1999. Regional heterogeneity and intra-observer variability of DNA-content and cell proliferation markers determined by flow cytometry in head and neck tumours. Oral Oncol 35:217-223.
36. Furuya T, Uchiyama T, Murakami T, Adachi A, Kawauchi S, et al. 2000. Relationship between chromosomal instability and intratumoral regional DNA ploidy heterogeneity in primary gastric cancers. Clin Cancer Res 6:2815-2820.
37. Lyng H, Beigi M, Svendsrud DH, Brustugun OT, Stokke T, et al. 2004. Intratumor chromosomal heterogeneity in advanced carcinomas of the uterine cervix. Int J Cancer 111:358-366.
38. Hessman O, Skogseid B, Westin G, Akerstrom G. 2001. Multiple allelic deletions and intratumoral genetic heterogeneity in MENI pancreatic tumors. J Clin Endocrinol Metab 86:1355-1361.
39. Saeki R, Nagai H, Kaneko S, Unoura M, Yamanaka N, et al. 2000. Intratumoral genomic heterogeneity in human hepatocellular carcinoma detected by restriction landmark genomic scanning. J Hepatol 33:99-105.
40. Khalique L, Ayhan A, Weale ME, Jacobs IJ, Ramus SJ, et al. 2007. Genetic intra-tumour heterogeneity in epithelial ovarian cancer and its implications for molecular diagnosis of tumours. J Pathol 211:286-295.
41. Sharma SV, Bell DW, Settleman J, Haber DA. 2007. Epidermal growth factor receptor mutations in lung cancer. Nature Rev Cancer 7:169-181.
42. Alvarado C, Beitel LK, Sircar K, Aprikian A, Trifiro M, et al. 2005. Somatic mosaicism and cancer: A micro-genetic examination into the role of the androgen receptor gene in prostate cancer. Cancer Res 65:8514-8518.
43. Sircar K, Gottlieb B, Alvarado C, Aprikian A, Beitel LK, et al. 2007. Androgen Receptor CAG Repeat Length Contraction in Diseased and Non-Diseased Prostatic Tissues. Prostate Cancer Prostatic Dis. (In press)
44. Bignold LP, Coghlan BL, Jersmann HP. 2006. Cancer morphology, carcinogenesis and genetic instability: A background. EXS 96:1-24.
45. Bielas JH, Loeb KR, Rubin BP, True LD, Loeb LA. 2006. Human cancers express a mutator phenotype. Proc Natl Acad Sci USA 103:18238-18242.
46. Vineis P, Berwick M. 2006. The population dynamics of cancer: A Darwinian perspective. Int J Epidemiol 35:1151-1159.
47. Reynolds T. 2003. Prostate cancer prevention trial yields positive results, but with a few cautions. J Natl Cancer Inst 95:1030-1031.
48. Bains W. 2004. Paradoxes of non-trivial gene networks: How cancer-causing mutations can appear to be cancer-protective. Rejuvenation Res 7:199-210.
49. To MD, Perez-Losada J, Mao JH, Hsu J, Jacks T, et al. 2006. A functional switch from lung cancer resistance to susceptibility at the Pas1 locus in Kras2LA2 mice. Nat Genet 38:926-930.
50. Salanti G, Sanderson S, Higgins JP. 2005. Obstacles and opportunities in meta-analysis of genetic association studies. Genet Med 7:13-20.
51. Haber DA, Bell DW, Sordella R, Kwak EL, Godin-Heymann N, et al. 2005. Molecular targeted therapy of lung cancer: EGFR mutations and response to EGFR inhibitors. Cold Spring Harb Symp Quant Biol 70:419-426.
52. McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Wong EW, et al. 2006. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta. PMID: 17126425 [Epub ahead of print].
53. Beesley AH, Palmer ML, Ford J, Weller RE, Cummings AJ, et al. 2006. Authenticity and drug resistance in a panel of acute lymphoblastic leukaemia cell lines. Br J Cancer 95:1537-1544.
54. Kern SE. Winter JM. 2006. Elegance, silence and nonsense in the mutations literature for solid tumors. Cancer Biol Ther 54:349-359.
55. Thomas RK, Baker AC, DeBiasi RM, Winckler W, LaFramboise T, et al. 2007. High-throughput oncogene mutation profiling inhuman cancer. Nat Genet 39:347-351.
56. Chanock SJ, Thomas G. 2007. The devil is in the DNA. Nat Genet 39:283-284.
57. Gottlieb B, Beitel LK, Trifiro MA. 2001. Somatic mosaicism and variable expressivity. Trends Genet 17:79-82.
58. Turker MS, Lasarev M, Connolly L, Kasameyer E, Roessler D. 2007. Age-related accumulation of autosomal mutations in solid tissues of the mouse is gender and cell type specific. Aging Cell 6:73-86.
59. Shin MG, Kajigaya S, Tarnowka M, McCoy JP Jr, Levin BC, et al. 2004. Mitochondrial DNA sequence heterogeneity in circulating normal human CD34 cells and granulocytes. Blood 103:4466-4477.